RAYDIAX Raises €7.5 Million in Series A1 Funding
RAYDIAX, a medical technology company based in Magdeburg, Germany, has successfully raised €7.5 million in a Series A1 funding round dated March 4, 2026. This funding will support the advancement of its therapy-assistance CT system, designed for aiding minimally invasive cancer interventions directly in operating rooms.
Investors and Funding Details
The funding round was led by bmp Ventures through the IBG funds, with participation from the GETEC Family Office, High-Tech Gründerfonds, and the European Innovation Council Accelerator. The European Commission’s EIC Accelerator program contributed €2.5 million of the total amount, with the remaining €5 million coming from venture capital provided by existing investors and business angels.
About RAYDIAX and Its Technology
Founded in 2022, RAYDIAX emerged from the STIMULATE research campus at Otto von Guericke University Magdeburg. The company has developed a unique CT imaging system known as TACT, which combines high-resolution 3D multislice CT imaging with large-area 2D angiography. This system is distinctive for its compact design, allowing fast modality switching and continuous procedural monitoring, optimized for use in minimally invasive cancer treatments.
The TACT system also features a one-meter free inner diameter and a free-floating patient table, enhancing ergonomic operation and access for surgical robots. It integrates a specialized API for closed-loop control and a full graphical interface for precise, telemanipulated, and robotic interventions.
Leadership Team
RAYDIAX was co-founded by Thomas Hoffmann, who serves as the CEO, alongside André Mewes, Benjamin Fritsch, Robert Frysch, and Tim Pfeiffer, all of whom are associated with the EXIST Research Transfer. CEO Thomas Hoffmann noted the significance of the funding milestone, stating: "With the successful closing of our Series A1, we have reached a decisive milestone on our path toward clinical application."
Use of Funds
The newly acquired funds will be utilized to conduct first-in-human studies of the TACT system and generate early clinical evidence. RAYDIAX aims to advance the system toward series maturity and establish sales, production, and quality structures to support its market launch. The company's efforts will also focus on expanding organizational capabilities in sales, manufacturing, and quality management as they prepare for initial commercial installations.
Future Outlook
As RAYDIAX progresses toward regulatory approval and broader commercialization of its TACT system, it aims to enhance treatment options for minimally invasive cancer therapies. By providing real-time imaging during procedures, the company seeks to improve outcomes and patient recovery times compared to traditional surgical methods.
RAYDIAX's innovative approach and the successful funding round position it well to make significant strides in the field of interventional oncology, potentially transforming how minimally invasive cancer treatments are conducted globally.